Breaking News

GSK, Wave Life Sciences Collaborate on Oligonucleotide Therapeutics

Will leverage Wave’s PRISM oligonucleotide platform and GSK’s expertise in genetics and genomics.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

GSK plc and Wave Life Sciences Ltd., a clinical-stage genetic medicines company, entered a strategic collaboration to advance oligonucleotide therapeutics, including Wave’s preclinical RNA editing program targeting alpha-1 antitrypsin deficiency (AATD), WVE-006. The four-year discovery collaboration combines GSK’s insights from human genetics, as well as its global development and commercial capabilities, with Wave’s discovery and drug development platform, PRISM.   Oligonucleotides are short ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters